Glucose-incretin interaction revisited [Review]
Pancreatic beta cell dysfunction is pivotal to the development of diabetes, and restoration of insulin action is of primary importance. Here, we present a review of the mechanism of insulin secretion by pancreatic beta cells and discuss the mutual interaction of signaling pathways in stimulus - secr...
Gespeichert in:
Veröffentlicht in: | ENDOCRINE JOURNAL 2011, Vol.58(7), pp.519-525 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Pancreatic beta cell dysfunction is pivotal to the development of diabetes, and restoration of insulin action is of primary importance. Here, we present a review of the mechanism of insulin secretion by pancreatic beta cells and discuss the mutual interaction of signaling pathways in stimulus - secretion coupling to better understand the scientific basis of pharmacological treatment for insulin secretion deficiency. Glucose stimulates insulin secretion via membrane depolarization by closure of ATP-sensitive K+ channels (KATP channels) and opening of L-type voltage-dependent Ca2+ channels. The resultant elevation of cytosolic free Ca2+ triggers insulin exocytosis. This is termed the “KATP-dependent pathway” and is shared by sulfonylurea, which closes KATP channels. Glucose also stimulates insulin release independent of its action on KATP channels. This is referred to as the “KATP-independent pathway,” the molecular basis of which remains elusive. In the pancreatic beta cell, incretin hormones increase cAMP level, which enhances glucose-stimulated insulin release by protein kinase A-dependent and -independent mechanisms. Importantly, cAMP does not directly augment Ca2+-stimulated insulin release per se. The stimulatory level of ambient glucose is an absolute requirement for incretin to enhance insulin release. Therefore, incretin/cAMP enhances KATP-independent insulinotropic action of glucose. The robust glucose-lowering effect of DPP4 inhibitor add-on in diabetic patients with sulfonylurea secondary failure is intriguing. With the clinical availability of DPP4 inhibitor and GLP-1 mimetics, the importance of the interactions between cAMP signaling and KATP channel-independent actions of glucose is reappraised. |
---|---|
ISSN: | 0918-8959 1348-4540 |
DOI: | 10.1507/endocrj.EJ11-0064 |